Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Apr;175(4):781-9.
doi: 10.1086/513971.

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

R T Davey Jr  1 , D G Chaitt, S C Piscitelli, M Wells, J A Kovacs, R E Walker, J Falloon, M A Polis, J A Metcalf, H Masur, G Fyfe, H C Lane
Affiliations

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

R T Davey Jr et al. J Infect Dis. 1997 Apr.

Abstract

The safety and efficacy were assessed of 5-day cycles of subcutaneous (sc) interleukin-2 (IL-2) every 8 weeks in human immunodeficiency virus type 1-infected outpatients with >200 CD4 cells/mm3. Immunologic, virologic, and toxicity parameters were measured in 18 patients receiving standard antiretrovirals plus 5-day courses of sc IL-2 (3-18 MIU/day) every 2 months. Systemic toxicities established the maximally tolerated dose (MTD) of IL-2 as 15 MIU/day. CD4 cell responses appeared to correlate directly with baseline CD4 cell counts, with several patients experiencing a dramatic rise after 3 cycles. Virus load increased only transiently in the peri-injection period. It was concluded that serial cycles of outpatient sc IL-2 can be administered safely, with an MTD of 15 MIU/day. Patients with higher baseline counts appear to have a greater CD4 cell response to sc IL-2 therapy.

PubMed Disclaimer

Publication types